Wolverine Trading’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $58.3M | Buy |
1,050,900
+602,800
| +135% | +$35.3M | 0.04% | 286 |
|
|
2025
Q2 | $30.7M | Sell |
448,100
-60,400
| -12% | -$4.11M | 0.03% | 344 |
|
|
2025
Q1 | $35.2M | Buy |
508,500
+58,900
| +13% | +$4.86M | 0.04% | 278 |
|
|
2024
Q4 | $38.5M | Buy |
449,600
+61,200
| +16% | +$6.62M | 0.04% | 292 |
|
|
2024
Q3 | $46.9M | Sell |
388,400
-13,000
| -3% | -$1.73M | 0.05% | 219 |
|
|
2024
Q2 | $57.3M | Buy |
401,400
+33,200
| +9% | +$4.4M | 0.06% | 174 |
|
|
2024
Q1 | $47.3M | Buy |
368,200
+184,100
| +100% | +$21.9M | 0.05% | 203 |
|
|
2023
Q4 | $19M | Sell |
184,100
-128,400
| -41% | -$12.7M | 0.02% | 464 |
|
|
2023
Q3 | $28.4M | Buy |
312,500
+192,700
| +161% | +$17M | 0.03% | 275 |
|
|
2023
Q2 | $9.41M | Buy |
119,800
+64,800
| +118% | +$5.29M | 0.01% | 617 |
|
|
2023
Q1 | $4.35M | Sell |
55,000
-200
| -0.4% | -$14.2K | 0.01% | 917 |
|
|
2022
Q4 | $3.73M | Sell |
55,200
-9,000
| -14% | -$528K | 0.01% | 1042 |
|
|
2022
Q3 | $3.22M | Buy |
+64,200
| New | +$3.44M | 0.01% | 1093 |
|
|
2022
Q2 | – | Sell |
-24,800
| Closed | -$1.4M | – | 5340 |
|
|
2022
Q1 | $1.4M | Sell |
24,800
-157,800
| -86% | -$8.1M | ﹤0.01% | 2107 |
|
|
2021
Q4 | $10.2M | Buy |
182,600
+106,200
| +139% | +$5.75M | 0.01% | 718 |
|
|
2021
Q3 | $3.67M | Buy |
76,400
+45,000
| +143% | +$2.18M | ﹤0.01% | 1555 |
|
|
2021
Q2 | $1.32M | Buy |
31,400
+14,400
| +85% | +$558K | ﹤0.01% | 2470 |
|
|
2021
Q1 | $577K | Buy |
+17,000
| New | +$605K | ﹤0.01% | 3502 |
|
|
2020
Q3 | – | Sell |
-64,600
| Closed | -$2.12M | – | 4950 |
|
|
2020
Q2 | $2.12M | Buy |
+64,600
| New | +$2.06M | 0.01% | 1366 |
|
|
2020
Q1 | – | Sell |
-73,400
| Closed | -$2.12M | – | 5067 |
|
|
2019
Q4 | $2.12M | Buy |
73,400
+11,000
| +18% | +$305K | 0.01% | 1790 |
|
|
2019
Q3 | $1.61M | Buy |
62,400
+27,400
| +78% | +$693K | ﹤0.01% | 1591 |
|
|
2019
Q2 | $893K | Buy |
35,000
+9,000
| +35% | +$222K | ﹤0.01% | 2154 |
|
|
2019
Q1 | $680K | Sell |
26,000
-28,200
| -52% | -$693K | ﹤0.01% | 2452 |
|
|
2018
Q4 | $1.24M | Sell |
54,200
-25,600
| -32% | -$569K | ﹤0.01% | 1801 |
|
|
2018
Q3 | $1.88M | Buy |
79,800
+59,200
| +287% | +$1.44M | ﹤0.01% | 1730 |
|
|
2018
Q2 | $507K | Hold |
20,600
| – | – | ﹤0.01% | 3087 |
|
|
2018
Q1 | $507K | Buy |
+20,600
| New | +$541K | ﹤0.01% | 3087 |
|
|
2017
Q4 | – | Sell |
-35,400
| Closed | -$852K | – | 5306 |
|
|
2017
Q3 | $852K | Buy |
35,400
+17,600
| +99% | +$398K | ﹤0.01% | 2047 |
|
|
2017
Q2 | $377K | Sell |
17,800
-22,600
| -56% | -$456K | ﹤0.01% | 2727 |
|
|
2017
Q1 | $683K | Buy |
40,400
+7,800
| +24% | +$136K | ﹤0.01% | 2058 |
|
|
2016
Q4 | $585K | Sell |
32,600
-9,600
| -23% | -$174K | ﹤0.01% | 2449 |
|
|
2016
Q3 | $882K | Buy |
+42,200
| New | +$1.05M | ﹤0.01% | 1995 |
|
Other funds holding NVO
F
Wolverine Trading's NVO Position: Q3 2025 in Review
Wolverine Trading reduced its Novo Nordisk (NVO) stake by 85% in Q3 2025, selling an estimated $3.24M and leaving 9,629 shares worth $534K. The position accounts for ﹤0.01% of the portfolio, ranked #3633.
Wolverine Trading first reported a position in NVO in Q1 2017 and has held it in 25 quarters since. The position peaked at $10.7M in Q2 2024. 1,395 funds tracked by Wall St. Rank hold NVO as of Q3 2025.
- Wolverine Trading held 9,629 shares of Novo Nordisk worth $534K as of Q3 2025.
- Wolverine Trading sold 55,416 Novo Nordisk shares in Q3 2025, an estimated $3.24M.
- Novo Nordisk made up ﹤0.01% of Wolverine Trading's portfolio in Q3 2025, its #3633 holding.
- Wolverine Trading first reported a position in Novo Nordisk in Q1 2017 and has held it in 25 quarters since.
- Wolverine Trading's Novo Nordisk position peaked at $10.7M in Q2 2024.
- 1,395 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2025.
Based on Wolverine Trading's 13F filing for Q3 2025, filed 14 Nov 2025.